-
Brefeldin A Workflows for ER Stress and Trafficking
2026-09-22
Brefeldin A connects ER-to-Golgi transport failure with measurable secretion defects, Golgi remodeling, ER stress, and cancer-cell phenotypes. This workflow-focused guide shows how to optimize exposure, separate trafficking effects from apoptosis, and translate UPR biology into reproducible assays.
-
Purmorphamine: Making Smo Biology Translational
2026-09-21
Purmorphamine is more than a pathway activator: it is a controllable Smoothened agonist for connecting receptor engagement with transcriptional, osteogenic, neural, and sensory phenotypes. This thought-leadership article interprets honeybee Smo findings alongside bone and mesenchymal stem cell workflows, while emphasizing dose, formulation, species, and endpoint validation.
-
Quercetin Workflows for PI3K and Neuroinflammation
2026-09-21
Use Quercetin as a practical PI3K inhibitor and multi-pathway research probe across cancer research and neuroinflammation models. This workflow connects solvent handling, mitochondrial apoptosis, cell cycle regulation, and NLRP3-focused assays while separating evidence-backed findings from optimization recommendations.
-
Vitamin D/VDR Control of Endometrial Decidualization
2026-09-20
The 2026 International Journal of Endocrinology study identifies a VDR-dependent mechanism through which 1,25-dihydroxy vitamin D3 promotes human endometrial stromal cell decidualization. Its data connect vitamin D metabolism with CYP19-mediated estrogen signaling, providing a mechanistic framework for studying endometrial receptivity while highlighting important limits on clinical and cross-tissue interpretation.
-
AO/PI Double Staining Kit: Practical Guide
2026-09-19
The AO/PI Double Staining Kit supports rapid fluorescent separation of viable, apoptotic, and necrotic cell populations when membrane status and nuclear staining patterns can be evaluated together. It is suitable for research cell viability assays and preliminary apoptosis or necrosis detection, but it should not be treated as a standalone confirmation of a specific cell-death pathway or used with fixed and permeabilized samples without separate validation.
-
Heat-Not-Burn Product Genotoxicity: Evidence and Limits
2026-09-19
The reference study combines rat exposure experiments with a broad in vitro genetic-toxicology panel to compare a heat-not-burn product with conventional cigarettes. Its results indicate lower cytotoxicity and genotoxicity for the tested heat-not-burn product under the specified conditions, while also showing why product-specific exposure models and multiple endpoints are essential for interpretation.
-
Palonosetron and Chemotherapy-Induced Nausea and Vomiting
2026-09-18
The reference article presents a focused pharmacologic and clinical review of palonosetron hydrochloride, emphasizing its long half-life, high 5-HT3-receptor affinity, and distinctive allosteric binding behavior. Its practical contribution is a cautious interpretation of whether these properties improve acute and delayed chemotherapy-induced nausea and vomiting control compared with earlier 5-HT3 antagonists.
-
gamma-Glu-Cys (γ-Glu-Cys) Workflow Guide
2026-09-18
This guide explains how to handle gamma-Glu-Cys (γ-Glu-Cys), a glutathione biosynthesis intermediate used in glutathione synthetase enzyme assay development, peptide workflows, and plant research. It provides product-specific specifications and practical QC recommendations, while emphasizing that the material is for controlled research use and not for diagnostic, clinical, or medical applications.
-
Regorafenib Workflows for Melanoma Research
2026-09-17
Build mechanism-led melanoma, angiogenesis, and migration experiments with Regorafenib (BAY 73-4506). This workflow connects multikinase inhibition to RRM2 and ERK/E2F3 biology while emphasizing dose selection, orthogonal readouts, and troubleshooting.
-
Betulinic Acid Protects Against Cyclophosphamide Liver Injur
2026-09-17
This study identifies an ERK-linked mitochondrial apoptotic mechanism in cyclophosphamide-induced liver injury and shows that betulinic acid reduces oxidative damage, mitochondrial dysfunction, and hepatocyte apoptosis in mice. Its combined use of antioxidant, signaling, mitochondrial, and pharmacological-intervention data provides a useful framework for evaluating hepatoprotective mechanisms.
-
Lambda Protein Phosphatase for BMAL1 Validation
2026-09-16
Use Lambda Protein Phosphatase to separate phosphorylation-dependent BMAL1 behavior from antibody artifacts, sample variation, and condensate assay noise. The workflow combines controlled dephosphorylation, phospho-antibody validation, and functional phase-separation readouts.
-
OX40L mRNA: Designing Co-Stimulation Assays
2026-09-15
EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) enables a structured way to study ligand display, OX40-dependent signaling, and functional T-cell co-stimulation. This guide translates related mRNA immunotherapy evidence into rigorous controls and interpretation criteria without overstating what the literature proves.
-
PTX3–TLR4/NF-κB Axis in Glucocorticoid ONFH
2026-09-15
The reference study identifies a protective PTX3–TLR4/NF-κB–FGF21 signaling axis in glucocorticoid-induced osteonecrosis of the femoral head (ONFH). Its gain-of-function, loss-of-function, pathway-blockade, and downstream-rescue experiments position FGF21 as an actionable effector while clarifying how PTX3 may preserve osteogenesis and limit apoptosis.
-
Erastin as a Ferroptosis Assay Benchmark
2026-09-14
Erastin is a ferroptosis inducer that can serve as a mechanistic reference for studying redox failure, iron mobilization, and tumor-cell radiosensitization. This article translates recent GPR68 research into a practical assay framework that separates pathway initiation from ferroptotic execution.
-
Regorafenib, RRM2, and Melanoma Progression
2026-09-14
A 2024 iScience study identifies RRM2 as a mechanistically important downstream effector of Regorafenib in melanoma. By combining phenotypic assays, RNA sequencing, perturbation and rescue experiments, and tumor xenograft validation, the work links multikinase inhibition with ERK/E2F3-associated control of melanoma growth, invasion, metastasis, and apoptosis.